The partnership will further the system’s research and development of cell-targeted nucleic acid and gene editing therapies which Pfizer may apply to its investigational programs, according to a Feb. 12 system news release. It will also bring together UT Southwestern’s advances in RNA-based biology and therapies with Pfizer’s rapid manufacturing capabilities.
UT Southwestern’s lab has been working on RNA-based delivery systems for more than a decade.
